# David Stassen

> David Stassen is a Series A investor at Split Rock Partners backing Health Care and Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Split Rock Partners](https://shizune.co/investors/profile/split-rock-partners)
- Location: San Francisco, United States
- Total investments: 9
- Last investment: Feb 2019
- Lead investor: 11%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/david-stassen-06335860

David Stassen is a Series A investor at Split Rock Partners in San Francisco focused on Health Care and Medical. David Stassen is the Co-Founding Managing Director of Split Rock Partners & he attended University of St. Thomas in 1969.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 33% |
| Medical | 2 | 22% |
| Biotechnology | 2 | 22% |
| Medical Device | 2 | 22% |
| Information Technology | 1 | 11% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 22% |
| Series B | 2 | 22% |
| Series C | 2 | 22% |
| Series D | 2 | 22% |
| Series E | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nuvaira | Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $79M | Series E | Feb 11, 2019 |  |
| Zyga Technology | Zyga Technology is a surgical solutions provider developing & commercializing medical devices for treating spine problems. In addition to the SImmetry Sacroiliac Joint Fusion System, the company is also developing the Glyder Facet Restoration Device. Zyga has put together a team of engineers, marketing personnel, and management with significantexperience developing medical devices for the spine industry.Zyga Technology was founded in 2008 and is headquartered in Minnesota, USA. | $2M | Series D | Sep 25, 2014 |  |
| Nuvaira | Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $42M | Series D | Apr 03, 2014 |  |
| Nuvaira | Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $10M | Series C | Feb 08, 2013 |  |
| Nuvaira | Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $10.6M | Series B | Sep 20, 2012 |  |
| Zyga Technology | Zyga Technology is a surgical solutions provider developing & commercializing medical devices for treating spine problems. In addition to the SImmetry Sacroiliac Joint Fusion System, the company is also developing the Glyder Facet Restoration Device. Zyga has put together a team of engineers, marketing personnel, and management with significantexperience developing medical devices for the spine industry.Zyga Technology was founded in 2008 and is headquartered in Minnesota, USA. |  | Series C | May 16, 2012 |  |
| Nuvaira | Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. |  | Series A | Sep 29, 2010 |  |
| Nexis Vision | Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC. |  | Series B | Jun 18, 2009 |  |
| Nexis Vision | Nexis Vision develops ophthalmic solutions. The company is developing ocular surface technology for ophthalmic devices. The company was founded in 2007 and is based in Menlo Park, California. Nexis Vision, Inc. operates as a subsidiary of ForSight Labs, LLC. |  | Series A | Jan 07, 2008 |  |

9 of 9 investments shown.

## Co-investors
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 8 deals together
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 4 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 4 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [MB Venture Partners](https://shizune.co/investors/profile/mb-venture-partners) — VC Fund, 2 deals together
- [Vertex Ventures HC](https://shizune.co/investors/profile/vertex-ventures-hc) — VC Fund, 2 deals together

## About Split Rock Partners

VC Fund · Minneapolis, United States

Split Rock Partners invests in emerging healthcare, software and Internet services companies in the Upper Midwest and West Coast. They are an early-stage venture capital firm that was founded in June 2004 by the former healthcare and software investment teams of St. Paul Venture Capital (SPVC). The Split Rock team managed over $1 billion of venturecapital during our tenure at SPVC, and continues to manage the SPVC healthcare and software portfolio. In May of 2008, they raised $300 million in the second Split Rock Partners fund, the successor to their inaugural $275 million fund raised in April 2005.The Split Rock team believes that it takes great people to translate promising ideas into compelling businesses. They are grounded in a fundamental respect for entrepreneurs and the rare combination of elements required when pioneering new markets. They start by looking for entrepreneurs with the passion, vision, and skills to build leading companies. They then work with entrepreneurs collaboratively, building partnerships based on integrity and mutual respect. The Split Rock team complements management expertise with over 80 years of venture investing and entrepreneurial management experience. They are proud of the strong relationships they have built with talented entrepreneurs and co-investors throughout their history and look forward to building on that tradition.

4 contacts available at Split Rock Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Jim Simons | Co-Founding Managing Director | https://shizune.co/investors/profile/jim-simons |
| David Stassen | Co-Founding Managing Director | https://shizune.co/investors/profile/dave-stassen |
| Michael Gorman | Co-Founding Managing Director | https://shizune.co/investors/profile/michael-gorman |
| Steven Schwen | CFO | https://shizune.co/investors/profile/steve-schwen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does David Stassen invest in?

David Stassen invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Stassen last invest?

The most recent investment recorded for David Stassen closed in Feb 2019. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co